Diabetic Kidney Disease Market Size, Share, and Trends 2024 to 2034

Diabetic Kidney Disease Market (By Type: Type 1 Diabetes, Type 2 Diabetes; By Treatment: Angiotensin Receptor Blockers Angiotensin-Converting Enzyme Inhibitors, Antioxidant Inflammation Modulator, Calcium Channel Blockers, Others; By Distribution Channel: Online Pharmacy, Hospital Pharmacy, Retail Pharmacy) - Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2023-2032

  • Last Updated : December 2022
  • Report Code : 2497
  • Category : Healthcare

The global diabetic kidney disease market size was estimated at USD 2.5 billion in 2022 and it is projected to hit around USD 4.19 billion by 2032, growing at a CAGR of 5.3% from 2023 to 2032

Diabetic Kidney Disease Market Size 2023 To 2032

To Access our Exclusive Data Intelligence Tool with 15000+ Database, Visit: Precedence Statistics

Key Takeaways

  • On the basis of type, the type 2 segment is anticipated to maintain its market dominance with the highest market share from 2023 to 2032.
  • On the basis of treatment, the angiotensin-converting enzyme (ACE) Inhibitors segment has the largest market share.
  • On the basis of distribution channels, the retail pharmacy and drug store segment contributed the highest revenue in 2022.
  • On the basis of geography, the North America region captured the largest market share in 2022.

Diabetic Kidney Disease Market Overview

Kidney illness brought on by diabetes accounts for a significant portion of all diseases worldwide. The prevalence of obesity and diabetes is rising worldwide, fueling the market for diabetic nephropathy to proliferate. Genetics, blood sugar management, and blood pressure are a few other risk factors that can aid in the development of kidney disease in diabetes patients. Rising demand for diagnostic tests, including urine, blood, and kidney biopsy, as well as imaging tests like CT scans and MRI, are other factors driving market expansion.

Strict regulatory regulations, prolonged medication approval processes, and a shortage of comprehensive therapeutic management for diabetic nephropathy are all impeding the growth of the diabetic nephropathy market. Additionally, the high cost of imaging devices and the accuracy and dependability of a diagnostic test for the diagnosis of diabetic nephropathy restrict market expansion. Nevertheless, improvements in healthcare infrastructure in developing nations can generate a massive opportunity for market expansion and significantly boost market growth throughout the forecast period. Additionally, the market is growing due to the robust growth of the medical device sector and the accessibility of cutting-edge diagnostic tools.

Diabetic Kidney Disease Market Scope

Report Coverage Details
Market Size in 2022 USD 2.5 Billion
Market Size by 2032 USD 4.19 Billion
Growth Rate from 2023 to 2032 CAGR of 5.3%
Base Year 2022
Forecast Period 2023 to 2032
Segments Covered By Type, By Treatment, By Distribution Channel
Regions Covered North America, Europe, Asia-Pacific, Latin America, Middle East & Africa

Diabetic Kidney Disease Market Dynamics

Diabetes and chronic kidney disease (CKD) are challenging to treat. Still, there are several promising drugs in the pipeline for diabetic nephropathy, including esaxerenone (Daiichi Sankyo), TMX-049 (Teijin America), bardoxolone methyl (Kyowa Kirin), and others that are at various stages of clinical development. Essential treatments like Invokana, Farxiga, and Kerendia have paved the road for upcoming therapies with the latest medicine approval.

As diabetes cases continue to rise, the market for diabetic nephropathy will expand, allowing businesses to introduce innovative treatments. Additionally, the disease's better understanding in recent years will enable new targets to enhance treatment plans. Diagnostic techniques have benefited from technological advancements, and clinical recommendations establishing suggested targets and clinical practice have been published. It will be easier to manage and stop the course of diabetic nephropathy if indicators for early identification are found in patients. Furthermore, individuals with diabetic nephropathy are receiving tailored treatment to enhance renal and cardiovascular protection.

However, managing diabetic nephropathy is difficult due to the lack of novel therapeutic approaches to prevent, halt, cure, and reverse the disease and variations in clinical presentation and development rates among individuals. Additionally, the lack of routine screening and the lack of early and precise risk classification for patients with diabetic kidney disease (DKD)is troubling. Concerns have been raised about the usefulness of these models in preclinical drug discovery due to the absence of animal models that replicate the clinical characteristics of human DKD. Ineffective therapy is caused by poor drug adherence, which accelerates disease-related consequences. Renin-angiotensin system (RAS) inhibition and risk-factor management have been the accepted standards of care for management for the past 20 years.

Covid-19 Impact

The rise in kidney-related disorders is directly correlated with the rising COVID-19 incidence. For instance, according to a paper from 2021 titled "Acute Renal Injury in COVID-19: 90 Days of the Pandemic in a Brazilian Public Hospital," the kidneys are involved in 4–37% of COVID–19 cases, and acute kidney disorders are 50% more common in COVID–19 patients who are hospitalized. As a result, it has been discovered that the COVID-19 virus significantly affects patients' kidneys, which is anticipated to increase the burden of renal problems shortly and fuel market expansion. So, COVID-19 substantially affects the market for kidney illnesses worldwide.

Segments Insight

The kidney disease market is divided into segments based on type, treatment, distribution channel, and geography. By enlarging these divisions, you'll be able to research the industries' sparse growth sectors and provide users with thorough market summaries and industry insights to help them identify the most critical market applications.

Diabetic Kidney Disease Market Share, By Type, 2022 (%)

Type Insights

Based on type, the market is divided into Type 1 Diabetes and Type 2 Diabetes. During the projected period, Type 2 is anticipated to maintain its market dominance with the highest market share. Due to the widespread occurrence of diabetic nephropathy (DN) in type 2 diabetic people aged 20 and older.

Distribution Channel Insights

Based on the distribution channel, the retail pharmacy and drug store segment contributed the highest revenue in the diabetic kidney disease market in 2021. During the forecast period, the online provider segment is anticipated to see the highest CAGR, owing to the rise in the population suffering from diabetes and the geriatric population.

Treatment Insights

Based on treatment, Angiotensin Receptor Blockers (ARBs), angiotensin-Converting Enzyme (ACE) Inhibitors, Antioxidant Inflammation Modulators, Calcium Channel Blockers, and Others are the market segments. The Angiotensin-Converting Enzyme (ACE) Inhibitors sector has the largest market share. This is due to the safety and effectiveness of particular diabetic nephropathy-related symptoms.

Regional Insights

The United States, Canada, and Mexico are the major nations covered in the global kidney disease market report. Other significant countries include Germany, France, the United Kingdom, the Netherlands, Belgium, Switzerland, Italy, Russia, Spain, and Turkey, as well as the rest of Europe, Japan, China, South Korea, India, Malaysia, Singapore, Thailand, Australia, Indonesia, and the Philippines as well as the rest of Asia-Pacific (APAC), Saudi Arabia, the United Arab Emirates, South Africa, Egypt, and Israel as well as the rest of Middle East and Africa (MEA).

Due to rising government and pharmaceutical organization efforts to raise awareness of kidney disease as well as the existence of generic manufacturers, Europe has experienced the highest increase in the market worldwide.

As technology for treating renal disorders develops and pharmaceutical companies ramp up their efforts to create new formulations, North America now controls the market.

The study's regional section also lists specific market-impacting elements and domestic market regulation changes that affect the market's present and future trends. When giving prediction analysis of the country data, it also takes into account the presence and accessibility of international brands as well as the difficulties they encounter due to solid or weak competition from domestic and local brands, the influence of domestic tariffs, and trade routes.

Recent Developments

  • On May 2021, Novartis acquired cellerys, a research therapy startup from Zurich, to fight multiple sclerosis.
  • On January 2021, Mitsubishi Tanabe Pharma Corp. made a licensing agreement with Foods International Co. Ltd. to form a candidate antibody to cure antibody diseases.
  • On April 2021, the treatment of chronic kidney diseases in people at risk of progression with and without type-2 diabetes was approved in the US by Farxiga.
  • On October 2019, the United States designated Fresenius Medical Care as a breakthrough device manufacturer. A new hemodialysis device that promises to prevent blood clotting without the use of drugs has received approval from the FDA.

Competitive Analysis

The competitive landscape for the global kidney disease market includes information on competitors. The company's financials, market potential, revenue generated, investment in R&D, global presence, new market initiatives, production capacities, production sites and facilities, product launch, company weaknesses and strengths, product width and breadth, and application dominance are among the details that are included. The abovementioned data points are limited to the companies' attention to the global market for kidney illness.

Diabetic Kidney Disease Market Companies

  • AstraZeneca (UK.)
  • Pfizer Inc (US.)
  • Allergan,Inc (Ireland)
  • Bristol-Myers Squibb Company (US.)
  • Endo International plc (Ireland)
  • Dr. Reddy's Laboratories Ltd (India)
  • Sun Pharmaceutical Industries Ltd (India)
  • Teva Pharmaceutical Industries Ltd (Israel)
  • Novartis AG (Switzerland)
  • Mylan NV (US.)
  • CiplaInc (India)
  • Lupin (India)
  • Aurobindo Pharma (India)
  • Sanofi (France)
  • Fresenius SE & Co. KGaA (Germany)
  • F. Hoffmann-La Roche Ltd (Switzerland)
  • Takeda Pharmaceutical Company Limited (Japan)
  • Abbott (US.)

Segment Covered in the Report

By Type

  • Type 1 Diabetes
  • Type 2 Diabetes

By Treatment

  • Angiotensin Receptor Blockers (ARBs)
  • Angiotensin-Converting Enzyme (ACE) Inhibitors
  • Antioxidant Inflammation Modulator
  • Calcium Channel Blockers
  • Others

By Distribution Channel

  • Online Pharmacy
  • Hospital Pharmacy
  • Retail Pharmacy

By Geography

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East & Africa (MEA)

Frequently Asked Questions

The global diabetic kidney disease market size was accounted at USD 2.5 billion in 2022 and it is expected to reach around USD 4.19 billion by 2032.

The global diabetic kidney disease market is poised to grow at a CAGR of 5.3% from 2023 to 2032.

The major players operating in the diabetic kidney disease market are AstraZeneca, Pfizer Inc, Allergan, Inc, Bristol-Myers Squibb Company, Endo International plc, Dr. Reddy's Laboratories Ltd, Sun Pharmaceutical Industries Ltd, Teva Pharmaceutical Industries Ltd, Novartis AG, Mylan NV, CiplaInc, Lupin, Aurobindo Pharma, Sanofi, Fresenius SE & Co. KGaA, F. Hoffmann-La Roche Ltd, Takeda Pharmaceutical Company Limited, Abbott and Others.

The driving factors of the diabetic kidney disease market are the rise in kidney disease incidence and advancements in technology.

North America region will lead the global diabetic kidney disease market during the forecast period 2023 to 2032.

Proceed To Buy

USD 4900
USD 3800
USD 2100
USD 2100
USD 7500

Ask For Sample

No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client